CSL s Large Scale Cell Culture Facility
|
|
- Austen Day
- 6 years ago
- Views:
Transcription
1 BioProcess Network 20 th October 2011 CSL s Large Scale Cell Culture Facility Tim Hughes Sr. Dir. Clinical Manufacturing CSL
2 Objective How to maximise the opportunity to build a state-of-theart facility while minimising risks? Large scale facility scope Facility design needs Facility features Process features Project schedule
3 New Biotech Facility Drivers CSL in-house current capacity is sufficient for preclinical and early clinical-phase materials, but late-phase supplies are contracted to CMO. Due to the expense and length of clinical trials, there is a strong business case for in-house capability. Business case is strengthened by a strong product portfolio During clinical phases, advantageous to have the ability to respond rapidly to changes in material demands and processes
4 New Biotech Facility Risks Long build- and delivery timelines often mean that decisions to build are made early Delaying the build decision may delay speed-to-market and increase cost to build Risk of owning a redundant facility due to: Molecules failing to reach late-stage clinical study or market Technology becoming obsolete A redundant facility may have little resaleor reuse value due to geographic location, installations of major equipment and design philosophy
5 Facility Project Early Specifications Deliver a large scale cell culture facility Footloose location - multiple options Provide required capacity to cater for Phase III clinical trials and early market entry. Accommodate a range of process technologies including recombinant proteins and mabs. Comply with FDA, EU and TGA requirements. Leverage CSL worldwide group technical capabilities
6 Large Scale Cell Culture Facility Location 6 CSL Broadmeadows site chosen because of the proximity to CSL largescale cell culture expertise at Parkville, large-scale protein purification expertise at Broadmeadows and CSL research capability at Bio21 Institute, Melbourne. Commercial in Confidence
7 Facility: Key Features Must be able to handle multiple products and technologies at unknown scales and rates Flexibility of use and easy process change-over for campaigns Control highest risks Do not compromise product quality Reduce the risk of a redundant facility Limit capital exposure Delay decision to build as late as possible Control cost of goods Low COGS even at low capacity
8 Scope Limits Limit of installed scope 200L 500L 2000L Molecule 1 BDI BDS 2000L Limit of design scope 500L 2000L Molecule 2 BDI BDS 2000L Additional capacity for higher capacity and new products will be added when needed. Molecule 3 BDI BDS Ship BDI for processing at CSL Germany
9 Key Facility Feature: Flexibility Adaptable facility design, allowing incorporation of new technologies for maximum process/ product flexibility.
10 Decision: Facility Based on Single-Use Systems Benefits: Maximum flexibility in scale, alternative processes and technologies with minimum capital investment Fast change-over; reduced cycle times Risk control Higher assurance; no CIP or SIP required Lower capital investment; simpler/ cheaper build than conventional Facility may be reused for other purposes relatively easily Control cost of goods Decision to build may be delayed Fast build COGS is favourable for process and scales planned
11 Cost of Goods Cost of Goods with single-use Industry S-U Economic Consensus: Single-use in biotech are cost effective at low titres, low volumes and low utilisation rates Volume/ Titre/ Run rate Various references: BioPharm International, & BioPharm Services Inc.
12 Single-Use - Risks Higher batch operating expenses Rising cost due to hydrocarbon-source raw material Environmental cost and disposal costs Technology is immature, changing, unstandardised Supply chain concerns Viability of suppliers; single source; quality and reliability is untested Film changes, film variability More manual operations Ergonomics/ handling risks; Operator retraining Process scalability questions Mixing, aeration, flow rates etc. are different to conventional systems Production scale limited at ~2,000L Extractables and leachables questions Validation is more complex Chemical resistance; surface adsorption studies Nevertheless, facilities based on single-use are viable and approvable
13 Due Diligence for Facility and Process Design Approved Therapeutics: Visited several US companies with FDA approved products in singleuse systems Facility/ Processes: Consulted US thought-leader consultants in facility design and process engineering S-U Suppliers: Visited and audited vendors and their suppliers/ fabricators Process Integrators: Compared capability to provide integration of the entire process stream
14 Single-use: Challenges / Opportunities Process Adaptation Process must be adapted to volume & flow restrictions, technology limits, surface adsorption, potential gas penetration, higher extractables and leachables, different mixing characteristics & aeration strategies, etc. Validation Increased (& different) process validation Reduced services & utility requirements Reduced start-up & validation; No SIP and CIP QA Features Sterile, 100% containment feature of s-u items influences facility design: Gowning levels Process step segregation Reduced facility air classifications EM monitoring
15 Facility Design Outcomes Take the opportunity to simplify the conventional facility design model Use ballroom concept for processing areas, separated by process needs Install utility services with 75% turndown capability Use single-use where beneficial, s/s where sensible Use sterile process containers, closures and aseptic connectors on lines 1x 2,000L Upstream train; 1xDownstream train (+ space for more) Use off the shelf, interchangeable & upgradeable components on skids Mobile, modular skids with local controllers for process equipment Uplink skids with standardised, simple interfaces Initially no automated batch functionality or electronic batch records Design facility environment to match opportunities provided by s-u Locate open processing manipulations in HEPA hoods Design and certify at PC2-LS for future use (current cells: Level 1 risk) Increase validation at vendors sites to decrease on-site validation load
16 Project Schedule Design phases 1 & 2 started July 2009 Commenced construction Nov 2010 Complete mechanical/ process installation July 2012 Complete validation January 2013 Start Eng/GMP February 2013
17 Elevations FRONT (North) REAR (South) Commercial in Confidence
18 October 2011 Front view
19 Level 1 Layout Offices and Utilities FRONT Cold Storage Utilities Offices Commercial in Confidence
20 Level 2 Layout Process Floor FRONT Circulation Corridor Inoc Media Prep Buffer/Solution Prep Upstream Process Areas (to VI) Downstream Process (BDI) DS Viewing Corridor Commercial in Confidence
21 Model Process Pre-viral Post-viral
22 Air Quality- Area Classifications Upstream processing areas - Grade D/ ISO-9 Buffer preparation & BDI to DS processing - Grade C/ ISO-7 Open manipulations: Inoculum preparation (Grade C + Biosafety LAFU) Other open operations in BDI and DS, use sterile connectors
23 Level 2 HVAC Design Classifications FRONT Commercial in Confidence
24 Level 2 PC2-LS Certified Area FRONT
25 Liquid Waste Management GMO+ GMO- -40C freezer
26 Upstream Train Detail Single-use media prep Single-use inoculum train Shake flasks & Wave bags Single-use bioreactors 200L, 500L, 2000L, operable at 25% Lenticular clarification filters (no centrifuge)
27 Upstream Concept
28 Downstream Train Detail Stainless steel and single-use buffer prep S/s Chromatography skids, single-use flow path where feasible 60cm columns with multiple purification cycles for MAbs Single-use 30 cm columns In-line buffer dilution where possible UF/DF single-use flow path
29 Processing Single-use mixing skids with single-use sterile filtration Sterile bags inside totes for media, buffer and process hold Processing at ambient temperature Low temperature hold / storage: +4 o C, -40 o C & -70 o C
30 Buffer Prep Concept
31 Process Services WFI throughout Less cost than a large PW system + small WFI system Process gases Filtered compressed air Heat/cool packs Sterilisation autoclave Continuous heat decontamination unit
32 GMP Readiness The Operational GMP Readiness and Execution team (OGRE) has the prime objective: Ensure start-up of GMP processing on time OGRE comprises 12 workgroups with unique deliverables Workgroups comprise sub-teams Workgroups collaborate with other groups/ sub-teams
33 OGRE Stakeholders AdminServices - Security - Access - Reception - Mail/ courier Engineering/ Validation - Protocols - Execution Quality Management - Quality systems admin - Quality implementation - Documentation control - Vendor approvals - Audits - Product changeovers - Batch review - Analytical services - Product release - Process validation Communications - Stakeholder management - Publicity Staff Recruiting/ Training - Staff hiring - Staff orientation - Prescribed training Finance - Business entity - Pricing Engineering Services - Maintenance - Calibration - Primary utilities - Automation - Eng. vigilance OGRE GMP Ops 2013 Information Technology - Communications - BPCS Supply Chain - Material receiving - Released RM storage - Site logistics - Solid waste handling - Hazardous waste - Product shipping HS&E - Oversight - Certification - Specific training Technology Transfer - Analytical services - Specialist training - Technology transfers - Technical oversight - Trouble-shooting - Process qualification - Process validation Regulatory Compliance - Oversight - Agency liaison - Licensing
Quality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends
Quality & Regulatory Issues in Biopharmaceutical Facility Design A Perspective from Industry Trends Paul Smock, Biotechnology Quality & Technical Consultant Meridian BioGroup LLC The opinions and views
More informationDriving Value through Innovation in Biotech Manufacturing. Agenda
Driving Value through Innovation in Biotech Manufacturing Jorg Thommes, PhD Senior Vice President Operations Technology and Innovation Biogen 7 October 2015 Agenda Biopharma Legacy, Trends, & Challenges
More informationA Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody.
A Case Study on the Application of Disposable Technologies in cgmp Manufacturing Processes for a Therapeutic Antibody. Jeremy M Tong (presenting), Mark S Kettel, Edward M Perry, David J Pain, David M Valentine,
More informationSingle-use technology in downstream unit operations
Single-use technology in downstream unit operations ÄKTA ready chromatography system and more Madhu Raghunathan, Bioprocess capability days, Boston Imagination at work Presentation outline Introduction
More informationAdvancements on implementation of single use technology in vaccine manufacturing
Advancements on implementation of single use technology in vaccine manufacturing October 25 th, 2013 DCVMN Meeting Rio de Janeiro, Brazil Outline Overview of single use products Applications of single
More informationContinuous Processing Progress in Manufacturing
Cell World Conference, San Francisco, May 25-26 2017 Dr. Berthold Boedeker, Bayer AG, Biological Development Biologics at Bayer Regulatory support / drivers aof continuous processing Bayer s approach to
More informationSingle-Use Final Fill: Benefits and Considerations
Single-Use Final Fill: Benefits and Considerations TENDÊNCIAS DE TECNOLOGIAS DE FABRICAÇÃO E ASSÉPTICA DE MEDICAMENTOS Ana Luísa Lampert Cadore Sales Specialist SU & Aseptic Process Solutions ana.cadore@merckgroup.com
More informationApplication of Single-Use Equipment for Buffer Storage and Distribution in Medium Size mab Production Facility
Reprinted from PHARMACEUTICAL ENGINEERING THE OFFICIAL TECHNICAL MAGAZINE OF ISPE JANUARY/FEBRUARY 2014, VOL 34, NO 1 Copyright ISPE 2014 www.pharmaceuticalengineering.org facilities and equipment Application
More informationCell Therapy Services Your Product. Our Passion.
Pharma&Biotech Cell Therapy Services Your Product. Our Passion. Complete Portfolio of Services for cgmp Manufacturing of Cell-based Products Pharma&Biotech Cell Therapy Services for cgmp Manufacturing
More informationSingle-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer
Single-Use Products in BioManufacturing: Innovations Driving the Industry Bioprocess International SUPPLEMENT March 2011 By Eric Langer Biopharmaceutical manufacturers and CMOs are continuing to integrate
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Portrait of Rentschler Biotechnologie GmbH, a globally active service company that supports its clients in the development, production, and registration of biopharmaceuticals.
More informationThe Use of Disposable Technologies in Antibody Manufacturing Processes
The Use of Disposable Technologies in Antibody Manufacturing Processes Tim Matthews and Brad Wolk Process Development Engineering Genentech, Inc. South San Francisco, CA Outline Rationale for using disposable
More informationManufacturing Integrated Biologics Manufacturing
Manufacturing Integrated Biologics Manufacturing Integrated Biologics Manufacturing Abzena provides customer focused process development and manufacturing services for cgmp and non-gmp production of recombinant
More informationNovel Technologies in Plasma Fractionation. Dieter Fassnacht
Novel Technologies in Plasma Fractionation Dieter Fassnacht Agenda Grifols Overview Grifols Engineering Innovations in - Pooling - Fractionation - Filling Developing new technologies to provide innovative
More informationWHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES
WHEN, WHY AND HOW TO OUTSOURCE BIOMANUFACTURING: THE ROLE OF SINGLE USE TECHNOLOGIES John Coyne Sr. Manager: Bioprocessing Research and Development Manufacturing Pfizer, Inc. 23 Years Industry Experience,
More information,1+#$# 1)0'+!0',+!) -&!.*!"$10'"!)/ ",*-!+4 !/ %.,3+ 0.,+% *!+!%$*$+0 0$!* )2,0$"&
ALVOTECH 2017 ALVOGEN 9.5.2017 3 ALVOGEN WORLDWIDE 35 Alvogen worldwide offices BIOPHARMACEUTICALS ARE THE FUTURE Biologic molecules are the future of the pharmaceutical industry due to type of diseases
More informationImproving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns
Improving Bioprocessing Productivity Through the Application of Single-Use Protein A Columns By K. John Morrow, Jr. Ph.D. In the last two decades, the bioprocessing industry has confronted the demands
More informationFRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS
FRAUNHOFER INSTITUTE FOR MOLECULAR BIOLOGY AND APPLIED ECOLOGY IME INTEGRATED PRODUCTION PLATFORMS GMP-COMPLIANT PRODUCTION OF BIOPHARMACEUTICALS Close-up of large scale UF/DF control unit conditions and
More informationTom Sulpizio and Jeff Taniguchi, Advanced Minerals Corporation A Member of Imerys 130 Castilian Way, Santa Barbara, CA 93117
ADVANCES IN DISPOSABLE DIATOMITE FILTER AID SYSTEMS FOR CGMP BIOSEPARATIONS Session Pretreatment in Bioseparations AFSS Annual Meeting Valley Forge, PA May 20, 2008 ABSTRACT Tom Sulpizio and Jeff Taniguchi,
More informationGuiding Principles for the implementation of fluid management technologies for modern single use aseptic processing
Guiding Principles for the implementation of fluid management technologies for modern single use aseptic processing Jean-Marc Cappia, Vice President Marketing Fluid Management Technologies Agenda 1. Aseptic
More informationBiologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
More informationPharma&Biotech. ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful
Pharma&Biotech ADC Process Transfer from a CMO Perspective: How to Make a Collaboration Successful Additional Information and Disclaimer Lonza Group Ltd has its headquarters in Basel, Switzerland, and
More informationNADERI ENGINEERING, INC.
BIO-PHARMACEUTICAL ENGINEERING & VALIDATION CAPABILITIES "Cost Effective Solutions Through Innovation" 1240 Powell Street, Suite 2-B Emeryville, CA 94608 Tel: (510) 547-4040 Fax: (510) 547-4141 Website:
More informationIsolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite
APV 2008 Basle Conference Basle, Switzerland: May 28 & 29 2008 Isolators v. RABS: Facility Design Considerations for a Fill-Finish Finish Suite John R. Chester Principal Engineer Global Pharmaceutical
More informationAmazon FILTRATION SOLUTIONS PHARMACEUTICAL MANUFACTURING
Amazon FILTRATION SOLUTIONS PHARMACEUTICAL MANUFACTURING FILTRATION SOLUTIONS FOR PHARMACEUTICAL MANUFACTURING Delivering quality filtration products As one of Europe s leading manufacturers of process
More informationABL Europe s GMP manufacturing facility for viral vector production
ABL Europe s GMP manufacturing facility for viral vector production New Production Capacity for Viral Vectors Success Story ABL Europe GMP manufacturing of viral vectors from non-adherent cell cultures
More informationClare Simpson 21 st November Content courtesy of Steve Jones, Paul Illot, Bert Frohlich, Thomas Ryll Biopharm Services
Modelling a technology roadmap for acceleration of global industry innovation Presentation to Wales Life Science Hub, Health Economics Special Interest Group Clare Simpson 21 st November 2016 Content courtesy
More informationSteam Quality Testing
Offering the highest quality services by providing the knowledge and experience necessary for compliance within regulated industries, ultimately resulting in safe and healthy consumers. Commissioning /
More informationIn the biopharmaceutical industry,
S i n g l e - U s e TECHNOLOGIES Continuous Cell Culture Operation at 2,000-L Scale Michael Sherman, Vincent Lam, Melissa Carpio, Nick Hutchinson, and Christel Fenge In the biopharmaceutical industry,
More informationENERGIZE YOUR PROCESS
KORSCH offers a global service capability that addresses all facets of tablet production support and optimization. Our team of experienced experts provides far more than equipment repair and spare parts.
More informationOctober 10, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
October 10, 2017 Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: Docket No. FDA 2017 D 2802: Chemistry, Manufacturing, and Controls
More informationThe largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to
The largest network of harmonized bio/ pharmaceutical GMP product testing labs worldwide, Eurofins BioPharma Product Testing enables companies to advance candidates from development through commercialization
More informationEXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER
EXAMPLE OF VENDOR QUALIFICATION FOR IMMUNE EFFECTOR CELL PRODUCT MANUFACTURER Disclaimer: This example is just one potential example of a vendor qualification form to verify the adequacy of the internal
More informationIntegration of Risk Management into Product Strategy and Portfolio. Lori Richter Senior Consultant: QRM and Quality Systems ValSource, LLC
Integration of Risk Management into Product Strategy and Portfolio Lori Richter Senior Consultant: QRM and Quality Systems ValSource, LLC Focus for Today Leveraging ICH Q9 risk management concepts to identify
More informationPharma&Biotech. Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies
Pharma&Biotech Increasing Competitiveness of Legacy Stainless Steel Facilities in the Era of High Titer Processes and Single Use Technologies Elise-marie R. Beri / Lonza Seng Biologics /, Basel Inc / 10.
More informationHot Topics in Drug Product Process Validation: A Reviewer s Perspective
Hot Topics in Drug Product Process Validation: A Reviewer s Perspective Colleen Thomas, Ph.D. Quality Assessment Lead (Acting) FDA/CDER/OPQ/OPF Division of Microbiology Assessment CASSS CMC Strategy Forum
More informationAttachment C. Site Management and Control
Attachment C. Site Management and Control EPA Export 25-09-2015:22:43:46 Attachment C Management of the Installation C.1 Site Management and Control The organisation chart for the management of the Alexion
More informationAutomated in-line buffer preparation from readymade stock solutions in a mab process step
GE Healthcare Automated in-line buffer preparation from readymade stock solutions in a mab process step Buffer preparation is both time-and space-consuming and can easily become a challenge in biomanufacturing.
More informationMapping Success for Commercial Cell Therapy Manufacturing 100% 50% 0% 100% 50% 0% 100% 50% Realization
BioProcess TM I N T E R N A T I O N A L C e l l T h e r a p y FACILITIES AND LOGISTICS Mapping Success for Commercial Cell Therapy Bob Preti, Ann M. Daus, Brian Hampson, and Cenk Sumen Commercializing
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationThe biopharmaceutical industry
S i n g l e - U s e APPLICATIONS Understanding Particulates in Single-Use Bags Their Relationship to USP Chapter by Michael W. Johnson The biopharmaceutical industry is facing many challenges. Global
More informationCUSTOMER SERVICES YOUR PARTNERSHIP WITH THE WORLD LEADER IN INDUSTRIAL GASES
CUSTOMER SERVICES YOUR PARTNERSHIP WITH THE WORLD LEADER IN INDUSTRIAL GASES Air Liquide Group Air Liquide Engineering & Construction The world leader in gases, technologies and services for Industry and
More informationAseptic Process Validation
Aseptic Process Validation IMB GMP Information Seminar 27 th September 2012 Gerard Sheridan, Inspector Date Insert on Master Slide Slide 1 Overview Guidance Best Practices Common Deficiencies Slide 2 Aseptic
More informationVince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016
Quality Management in a Virtual Environment Vince Anicetti EVP Quality and Compliance, Coherus Biosciences West Coast PDA 20 October 2016 Biosimilars - the second wave of biotech -an evolving regulatory
More informationValidation of Sterilizing Grade Filters
Validation of Sterilizing Grade Filters Presented by Laura Okhio-Seaman Sartorius Corporation 1 Sterilizing Grade Filters The definition of a sterilizing grade filter is one that will produce a sterile
More informationApplication of Quality Risk Management Tools for Cell Therapy Manufacturing
Application of Quality Risk Management Tools for Cell Therapy Manufacturing 17 th ISCT Annual Meeting May 20, 2011 Jean Stanton Associate Director, Product Quality Management Janssen Supply Chain Conflict/Disclaimer
More informationA Journey in Global PUPSIT Implementation with Benchmarking. PDA Midwest Event Oct 5th, 2017 Jeff Gaerke P.E.
A Journey in Global PUPSIT Implementation with Benchmarking PDA Midwest Event Oct 5th, 2017 Jeff Gaerke P.E. Purpose Share learning on ongoing global implementation of PUPSIT for parenteral operations.
More informationFlexboy 2D Pre-designed Solutions for Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps
Storage Best Performance, Assurance of Supply and Closure Integrity for All Process Steps 2 Flexboy 2D Pre-designed Solutions Table Please click on the headline to go to the selected topic Digital Selection
More informationProcess Robustness & Challenges to Demonstrating Compliance
Process Robustness & Challenges to Demonstrating Compliance Nick Smith Head of Production & TSS 2 nd March 2017 95% Thomas Eldered 5% Management Headcount : 270 3 GMP facilities Cobra s Structure Cobra
More informationOverview of a sterility assurance program for PET drugs
Coalition for PET Drug Approval Radiopharmaceutical Sciences Council Overview of a sterility assurance program for PET drugs Eric Webster, PETNET Solutions Disclosures Employee of PETNET Solutions, a Siemens
More informationFood Safety & Quality in Aseptic Packaging for liquid food
Food Safety & Quality in Aseptic Packaging for liquid food ABCE, Dubai, October 29 th, 2017 Antonio Rendina Aseptic Performance Management Director Tetra Pak, DSO I would argue that Good data collection
More informationGuidance. Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE
Guidance Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography (PET) Drugs DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and
More informationIn the current competitive biopharmaceutical
Image Courtesy of Sartorius Stedim Biotech single-use Bioreactors for the rapid Production of Preclinical and clinical Biopharmaceuticals Rüdiger Heidemann, Christopher R. Cruz, Paul Wu, Mikal Sherman,
More informationCREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO
CREATING TOMORROW S SOLUTIONS BIOPHARMACEUTICALS I CONTRACT MANUFACTURING WACKER BIOTECH: THE MICROBIAL CMO STATE-OF-THE-ART GMP FACILITIES Our sites in Jena and Halle (Germany) provide a complete range
More informationGuide to Scientific and Regulatory Advice for GXP activities
Guide to Scientific and Regulatory Advice for GXP activities ADV-G0019-1 7 OCTOBER 2017 This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
More informationSterifix RELIABLE TECHNOLOGY FOR thermal wastewater
Thermal Wastewater Inactivation AND Sterilisation Sterifix RELIABLE TECHNOLOGY FOR thermal wastewater sterilisation and INActivating EnviroChemie offers intelligent solutions for reliable and decentralised
More informationRequest for Quote RFQ #
Request for Quote RFQ # 2017-007 Drug Product Manufacture: GMP Fill/Finish of Monoclonal Antibody I. Summary of Deadlines Release of Request for quote Feb 13, 2017 Confirmation of interest due by Feb 20,
More informationENERGY PERFORMANCE PROTOCOL QUALITY ASSURANCE SPECIFICATION
ENERGY PERFORMANCE PROTOCOL QUALITY ASSURANCE SPECIFICATION Version 1.0 April 2015 Table of Contents 1.0 INVESTOR CONFIDENCE PROJECT 1.1 ENERGY EFFICIENCY PERFORMANCE QUALITY ASSURANCE SPECIFICATION 1.2
More informationTrends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International
Trends in Perfusion Bioreactors: Will Perfusion Be the Next Revolution in Bioprocessing? June 15, 2011 BioProcess International Single-use/disposable bioprocessing equipment has come to thoroughly dominate
More informationMedia Fill A Process Simution. Presented By Shikha Chauhan
Media Fill A Process Simution Presented By Shikha Chauhan 21 CFR 211.113 Validation of Aseptic Processing and Sterilization Process Simulation / Media Fill Filtration Efficacy Sterilization of Equipment,
More informationThe validation of biological Active Pharmaceutical
This article presents a procedure for the validation of biological API manufacturing processes. It details each step of the procedure for biological processes applications, and covers the regulatory requirements
More informationThe interface between Good Clinical Practice and Good Manufacturing Practice
1 The interface between Good Clinical Practice and Good Manufacturing Practice your partner in compliance 1 The interface between GCP and GMP Generally, studies are designed and planned by physicians who
More informationSTERIS FINN-AQUA Pure Steam Generator for Pharmaceutical Manufacturing
cgmp MANUFACTURING STERIS FINN-AQUA Pure Steam Generator for Pharmaceutical Manufacturing Life Sciences STERIS Corporation has achieved worldwide leadership in the pharmaceutical and biotech industries
More informationPRAXIS. A publication by Bioengineering AG
PRAXIS A publication by Bioengineering AG Samsung BioLogics was founded in April 2011 and took only three years to establish itself as a global biotechnology contract manufacturer. One of the main reasons
More informationConducting Supplier Audits: Ensure Validation Compliance
Conducting Supplier Audits: Ensure Validation Compliance Presented by: Gamal Amer, Ph. D. Principal Premier Compliance Services, Inc. All rights reserved. Do not copy without permission. 1 Outline Why
More informationAnnex A2. Guidance on Process Validation Scheme for Aseptically Processed Products
Annex A2 Guidance on Process Validation Scheme for Aseptically Processed Products 1 Table of content 1 PURPOSE... 3 2 SCOPE... 3 3 GENERAL INFORMATION... 3 4 INFORMATION NEEDED FOR ASEPTIC PROCESSES VALIDATION...
More informationBIOPHARMACEUTICAL PROCESS EVALUATED FOR VIRAL CLEARANCE
The purpose of Viral Clearance evaluation is to assess the capability of a manufacturing production process to inactivate and/or remove potential viral contaminants. Experience and knowledge in selecting
More informationTetra Pak A Tetra Fino Aseptic
Tetra Pak A1 0800 Tetra Fino Aseptic We commit to making food safe and available, everywhere Tetra Pak A1 for Tetra Fino Aseptic is a filling machine for producing this simple and highly cost-competitive
More informationTrinity College Dublin QP Forum 2017 Tuesday 25 th April
Trinity College Dublin QP Forum 2017 Tuesday 25 th April HPRA QUESTIONS & ANSWERS 1. What is the approach being taken for audit of contamination control strategies as per chapters 3 & 5? What is the current
More informationBiology Lab Safety. Document No Audit Title Biology Lab Safety Inspection. Conducted on 9/28/16, 1:43 PM
Biology Lab ty Document No. 000089 Audit Title Biology Lab ty Inspection Conducted on 9/28/16, 1:43 PM Prepared by Travis Wood Lab ty Coordinator Completed on 9/28/16, 1:45 PM Report created with iauditor
More informationDevelopment of next-generation single-use films for optimal performance in biomanufacturing
Development of next-generation single-use films for optimal performance in biomanufacturing Susan Burke, PhD Bioprocess R&D GE Healthcare, Life Sciences Overview Importance of voice of customer in film
More informationImproved conventional practices of the pharma industry serving Cost of Goods of Autologous Cell Therapy
Tony Donolato Improved conventional practices of the pharma industry serving Cost of Goods of Autologous Cell Therapy Case Study: an Autonomous Tailor Made Isolator salamanderu: what we do? Regenerate
More informationHollow Fiber Bioreactors: Single-Use. Perfusion. Scalable. Continuous Manufacturing.
Bioreactors and BioServices for the Life of your Proteins Hollow Fiber Bioreactors: Single-Use. Perfusion. Scalable. Continuous Manufacturing. Presented by: Scott Waniger Vice President, BioServices BPI
More informationDHX Heat Exchanger. A new solution to heat transfer
DHX Heat Exchanger A new solution to heat transfer Sterile, efficient and modular The Thermo Scientific DHX Heat Exchanger is a modular system that employs a plate-and-frame concept, using a single-use
More informationDRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE
DRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE 1. This guidance provides clarity for test facilities on the expectations of national Good Laboratory
More informationStandard Scalable Flexel 3D Bioprocessing Bags
Standard Scalable Flexel 3D Bioprocessing Bags Fluid Management Systems Description Standard Scalable Flexel 3D Bioprocessing Bags are designed for processing and storage of small volume biopharmaceutical
More informationGMP Specific Considerations for ATMPs
uniqure 29. Oktober 2015 EMA / EuropaBio Information Day GMP Specific Considerations for ATMPs Alec Orphanidis Senior Vice President, Global Commercial Operations uniqure (Charmaine Augustinus-Lever Dir.
More informationABB Measurement & Analytics Monitoring cement plant stack emissions using FTIR
White paper WP/ANALYTICAL/002 EN ABB Measurement & Analytics Monitoring cement plant stack emissions using FTIR ABB FTIR CEMS analyzer successfully monitors cement plant stack emissions in extensive field
More informationinsite Integrity Testing System
insite Integrity Testing System Confidence at the point of use The power of knowledge As the value of processes increases with each step downstream, the value of sterility and leak detection becomes even
More informationSignatory Name: ALDI Stores (Australia) a Limited Partnership
Signatory Name: ALDI Stores (Australia) a Limited Partnership The question numbers in this report refer to the numbers in the report template. t all questions are displayed in this report. Status: Completed
More informationMulti-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities
Multi-column Continuous Capture Chromatography New data confirming significant savings and de-bottlenecking opportunities Dr.-Ing. Kathleen Mihlbachler, LEWA Bioprocess Repligen Seminar: Advances in Bioprocessing,
More informationXDR Single-Use Bioreactors
DATA SHEET XDR Single-Use Bioreactors Introduction The XDR Single-Use Bioreactor is a fully-integrated system that delivers proven stirred-tank performance across a wide range of cell lines. Single use
More informationSubject Index. chromatography step, 125-
A Alert limits, description, 70 Aluminum hydroxide based vaccine manufacture, start up and validation of sterile formulation and filling processes, 144-168 Anion-exchange chromatography step for clinical-grade
More informationThe Process Diagnostic. How to optimize the technology transfer and the development
The Process Diagnostic How to optimize the technology transfer and the development a does the on Introduction A critical aspect of industrialization is development. It is all about how to industrialize
More informationICH Q11 Development & manufacture of drug substances
ICH Q11 Development & manufacture of drug substances Keith McDonald Group Manager Medicines & Healthcare products Regulatory Agency (UK) 2011 ICH International Conference on Harmonisation of Technical
More informationMini filter cartridges and capsules for the biopharmaceutical industry
Mini filter cartridges and capsules for the biopharmaceutical industry Sartorius filter products designed for the pharmaceutical industry At Sartorius, we don t just sell you a filter. You work with experienced
More informationValidation. An Easy to Understand Guide Validating Purified Water Systems
Validation Overview Validation Documentation Validation Activities Validation Mistakes Validation Protocols Test Selection Common Verifications When to test Test Layout and Content Validation Protocol
More informationQMS CO-ORDINATOR & GENERAL PROCEDURES:-
1. QMS CO-ORDINATOR & GENERAL PROCEDURES:- (1) How do you measure effectiveness of system for working of your company? How do you collect necessary information for the same? Are you getting information
More informationOperational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production
UCL Decisional Tools Research Operational & Economic Evaluation of Integrated Continuous Biomanufacturing Strategies for Clinical & Commercial mab Production Suzanne Farid PhD CEng FIChemE Reader (Associate
More informationFlexsafe 3D Pre-Designed Solutions for Storage and Shipping Take Your Facility Into The Future
Flexsafe 3D Pre-Designed Solutions for Storage and Shipping Take Your Facility Into The Future 2 Flexsafe 3D Pre-designed Solutions Table Please click on headline to go to the selected page Digital Selection
More informationGE Healthcare s cell culture media, sera and process liquids
GE Healthcare s cell culture media, sera and process liquids upstream downstream single-use Global operational footprint Imagination at work. www.gelifesciences.com/hyclone services GE Healthcare BioProcess
More informationIN SITU STERILIZABLE BIOREACTORS
IN SITU STERILIZABLE BIOREACTORS Solida Biotechnology team with over 20 years experience in sterile process engineering and bioprocess technologies has realised a complete range of laboratory and pilot
More informationSirtex Medical Limited
Sirtex Medical Limited Market Update 2011 Half Year Results Gilman Wong CEO Darren Smith CFO 9-10 March 2011 SIR-Spheres is a registered trademark of Sirtex SIR-Spheres Pty Ltd. Understanding the Sirtex
More informationFDA s Guidance for Industry
Sterile Drug Products Produced by Aseptic Processing - CGMPs Midwest FDC Conference November 4 2005 Susan Bruederle, Investigator FDA / ORA / Central Region Chicago District / Hinsdale IL FDA s Guidance
More informationPrequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer
Part 1: General information Name of Manufacturer Production Block Physical address Contact address Prequalification Team WHO PUBLIC INSPECTION REPORT Vaccine Manufacturer. Clean Utilities in the Basement.
More informationREGULATORY AND BEST PRACTICES OVERVIEW. Process Filtration
REGULATORY AND BEST PRACTICES OVERVIEW Process Filtration COMPRESSED AIR GOOD MANUFACTURING PRACTICES - COMPRESSED AIR IN FOOD PLANTS Food and Drug Administration (FDA) Code of Federal Regulations (CFR)
More informationCurrent Trends in Sterile Manufacturing. by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS)
Current Trends in Sterile Manufacturing by Sterling Kline, RA Director of Project Development Integrated Project Services (IPS) Executive Summary Drug developers go to great lengths to assure that their
More informationCorrespondence between ICMED criteria and ISO 13485: 2012
Annexure A (Informative) Correspondence between ICMED 13485 criteria and ISO 13485: 2012 Green Font is additional ICMED 13485 criteria requirement. Additional ICMED 13485 criteria Requirements are also
More informationUNIFI 1.5 : Simplifying Qualification and Validation June 2012
UNIFI 1.5 : Simplifying Qualification and Validation June 2012 2011 Waters Corporation 1 Waters Regulated Bioanalysis System Solution Sample Preparation Solutions Best in class ACQUITY UPLC I-Class The
More informationAAMI Quality Systems White Paper: Comparison of 21 CFR Part 820 to ISO 13485:2016 1
AAMI s White Paper Comparison of 21 CFR Part 820 to ISO 13485:2016 February 2017 AUTHORS Seb Clerkin, GMP Advisory Services Nicola Martin, Owner, Nicola Martin Consulting Jack Ward, Owner, Ward Sciences
More information